Mergers and Acquisitions

Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal?

Litigation Photo

The investigation concerns whether the Immune Design board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Immune Design shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given that one Wall Street analyst has a $9.00 price target on the stock and the Company has approximately $100 million in cash and no long-term debt.

Read More »

Merck to Acquire Immune Design; Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer

Mergers and Acquisitions

“Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “This acquisition builds upon Merck’s industry-leading programs that harness the power of the immune system to prevent and treat disease.”

Read More »

Planet Green Holdings Stock Rose 331% Fueled By $10-Million Deal and Blue Gem

Planet Green Holdings Stock Rose 331 Percent Fueled by $50-Million Acquisition of 17.9 Blue Gem By Glenford S. Robinson Talk about a hyperbolic launch into space, Planet Green Holdings Corp. (NYSE: PLAG) did just that with its climactic rise into the stratosphere of 331% on Friday, launching from a day’s low of $2.85 to $11.51, with a trading volume of …

Read More »